Oxycontin giant’s guilty plea poses more questions than answers about opioid epidemic, according to WVU experts
A “disappointing” settlement that reveals a bent toward corporate profits over an “unfathomable amount of suffering” should lead to the shutdown of Purdue Pharma, according to West Virginia University experts who both work with people who face substance use disorder issues and have investigated the inner workings of the illicit side of the drug trade. Dr. Judith Feinberg, Dr. James Berry and John Temple are versed in various angles of the national opioid crisis are available to discuss the Justice Department’s $8.3 billion settlement with Purdue Pharma, the drug company that produces OxyContin. Purdue Pharma also agreed to plead guilty to three felonies.